Ceritinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ceritinib: From ALK-Positive Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Ceritinib is an oral ALK inhibitor, originally used to treat non-small cell lung cancer (NSCLC) and lung cancer. The TxGNN model predicts it may be effective for Gingival Fibromatosis, but there are currently 0 clinical trials and 0 publications supporting this specific prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Non-small cell lung cancer; lung cancer (the Singapore registration record contains no indication text) |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ceritinib is an anaplastic lymphoma kinase (ALK) inhibitor, its efficacy in ALK-rearranged NSCLC has been established, and the published literature describes it as a potent ALK inhibitor.
For gingival fibromatosis, however, no mechanistic link to ALK inhibition has been identified. The high score appears to be a knowledge-graph artifact rather than a biological rationale. Gingival fibromatosis is a benign overgrowth of gum tissue, and no trial or publication in the data compiled for this report connects it to ceritinib or ALK signalling.
Other top-ranked predictions show the same pattern. Several are lung-related (fibroma of lung, hamartoma of lung, lung hilum carcinoma, pulmonary sulcus neoplasm), likely reflecting proximity to lung cancer nodes in the graph. Others (e.g. junctional epidermolysis bullosa, a VCP-related myopathy syndrome) have no identified biological link. Of these, only lung hilum carcinoma and pulmonary sulcus neoplasm are plausibly ALK-relevant, and only if ALK-rearranged.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for gingival fibromatosis.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14776P | ZYKADIA CAPSULE 150mg | Capsule (oral) | Not stated in the registration record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (ALK tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; the literature also points to monitoring of renal function (ALK inhibitors raise serum creatinine), QT interval, and pulmonary symptoms (organizing pneumonia has been reported) |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction screening. Of the 20 listed in the data compiled for this report, most are Moderate. Major-level interactions are listed with triamcinolone and budesonide. Moderate-level examples include acid-reducing agents (famotidine, ranitidine, rabeprazole, omeprazole), other corticosteroids (hydrocortisone, dexamethasone, betamethasone), antidiabetic agents (metformin, pioglitazone, alogliptin, canagliflozin, acarbose, albiglutide), loperamide, aprepitant, and bisacodyl.
- Literature-based safety signals (from ceritinib and ALK inhibitor publications): organizing pneumonia, QT prolongation, hypersensitivity reactions, and kidney function effects.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for gingival fibromatosis is based only on a graph model score, with no clinical trials, no supporting literature, and no identified mechanistic link to ALK inhibition. The evidence level is L5. In addition, the safety profile of ceritinib, including a large number of drug interactions, makes use in a benign condition hard to justify without supporting data.
To proceed, the following is needed:
- Mechanism of action data and a biological rationale connecting ALK (or ceritinib's other targets) to gingival fibromatosis
- Preclinical or case-level evidence in the predicted indication
- Package insert warnings and contraindications from the Singapore regulator
- A benefit-risk assessment against existing treatments for benign gingival overgrowth
- If a lung-related prediction is pursued instead (e.g. lung hilum carcinoma or pulmonary sulcus neoplasm), confirmation of ALK rearrangement status and entity-specific evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.